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Abstract
Inclusion body myositis (IBM) belongs to a group of muscle diseases known as the inflammatory myopathies. The presence
of antibody-secreting plasma cells in IBM muscle implicates the humoral immune response in this disease. However,
whether the humoral immune response actively contributes to IBM pathology has not been established. We sought to
investigate whether the humoral immune response in IBM both in the periphery and at the site of tissue damage was
directed towards self-antigens. Peripheral autoantibodies present in IBM serum but not control serum recognized self-
antigens in both muscle tissue and human-derived cell lines. To study the humoral immune response at the site of tissue
damage in IBM patients, we isolated single plasma cells directly from IBM-derived muscle tissue sections and from these
cells, reconstructed a series of recombinant immunoglobulins (rIgG). These rIgG, each representing a single muscle-
associated plasma cell, were examined for reactivity to self-antigens. Both, flow cytometry and immunoblotting revealed
that these rIgG recognized antigens expressed by cell lines and in muscle tissue homogenates. Using a mass spectrometry-
based approach, Desmin, a major intermediate filament protein, expressed abundantly in muscle tissue, was identified as
the target of one IBM muscle-derived rIgG. Collectively, these data support the view that IBM includes a humoral immune
response in both the periphery and at the site of tissue damage that is directed towards self-antigens.
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Introduction
Inclusion body myositis (IBM) is an idiopathic inflammatory
myopathy. It is a progressive skeletal muscle disorder and has
a distinct clinical phenotype that includes weakness and atrophy
of distal and proximal muscles [1–4]. The clinical course
progresses slowly and often leads to severe debilitation. The
etiology and pathogenesis of IBM remain poorly understood, but
aging, genetics and environment may each play a role. The
salient features of disease pathology are inflammation and
myodegeneration [5]. IBM muscle biopsies are characterized
by an infiltration of CD8+ T cells associated with MHC class I
expression by the muscle fibers, vacuolization of muscle fibers
and accumulation of protein aggregates (termed inclusion bodies)
in the cytoplasm and nucleus [6]. Nodular collections of cells are
found within the endomysial and perimysial space [7]. It remains
unclear whether IBM is primarily a T cell-mediated or
myodegenerative disease [6,8], but each is thought to contribute
to the disease pathology [9].
The other major inflammatory myopathies, polymyositis and
dermatomyositis, include humoral autoimmunity evidenced by the
presence of autoantibodies and response to B cell depleting
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e46709therapy [10], although experience with the latter is limited. In
IBM, the humoral immune response has been studied to a lesser
extent than the T cell response because B cells and antibody-
secreting plasma cells were not, until recently, known to be present
in the damaged tissue. However, an abundance of differentiated B
cells, in the form of CD138
+ plasma cells, that populate the injured
tissue were recently identified [11,12]. The molecular character-
ization of these muscle-associated plasma cells indicated that these
cells were antigen-experienced and clonally expanded [7,12].
Furthermore, serum autoantibodies, in a subset of patients with
IBM, have been reported to react with a number of self-antigens
[13,14] with one study showing that approximately half of IBM
patients appear to harbor serum autoantibodies that react with an
unknown muscle antigen [15]. Finally, BAFF, a molecule crucial
for B cell maturation, survival and autoantibody production, is
elevated in a subset of patients with IBM [16]. These data suggest
that IBM may include humoral autoimmunity in addition to the
established T cell component of immunopathology.
Here we sought to examine whether the humoral immune
response in the periphery and at the site of muscle tissue damage
in IBM patients is directed towards self-antigens. We examined
serum-derived immunoglobulin for reactivity to both tissue and
tissue-derived cell lines. Immunohistochemistry revealed that IBM
serum IgG but not control IgG bound antigens in muscle tissue,
indicating that IBM serum harbors an immune response directed
to self-antigens. This was further confirmed with flow cytometry
on human cell lines. In addition, we examined the reactivity of the
local antibody response in IBM muscle tissue by generating
antibodies derived from individual plasma cells that were isolated
from the damaged tissue. Here we established that IBM muscle-
derived recombinant IgG (rIgG), but not control rIgG, bound
antigens expressed by human cell lines and present in muscle tissue
homogenates. Furthermore, we identified the intermediate
filament Desmin, a reported autoantigen in a number of
autoimmune conditions [17–19], as a target of the immunoglob-
ulin produced within the IBM muscle tissue. Collectively, these
data establish that humoral autoimmunity directed towards self-
antigens is present both in the periphery and at the site of tissue
damage in IBM patients.
Materials and Methods
Ethics Statement
Specimens originating from patients were collected after
informed written consent was obtained, under a protocol approved
by the Human Research Protection Program at Yale School of
Medicine. Specimens, that did not include personally identifiable
private information or intervention or interaction with an
individual, were collected under an exempt protocol approved
by the Human Research Protection Program at Yale School of
Medicine.
Patient-derived Specimens
Serum-derived IgG was obtained from 9 patients with IBM and
9 normal subjects. Collected sera were stored at 280uC. IgG was
purified from serum using Melon Gel IgG Purification kits
(Thermo Scientific) according to the manufacturer’s instructions.
This approach to isolation of IgG from serum was favored over
protein-G/A because Melon Gel does not require the use of harsh
elution conditions that can contribute to denaturation of the
immunoglobulins. IBM muscle biopsies, collected from four
patients, were snap frozen and stored at 280uC immediately
after collection. Biopsies were performed for clinical indications,
independent of the current study.
Cell Lines and Culture Conditions
Muscle-derived cell lines CRL-1598 and CCL-136, obtained
from ATCC, were cultured at 37uC, 5% CO2 in a humidified
chamber. Cell lines were grown in high glucose DMEM media
(Gibco) supplemented with 4 mM L-glutamine, 1 mM sodium
pyruvate and 10% FBS (Gibco). The human oligodendrocyte
(HOG) cell line [20] was grown in high glucose DMEM media
supplemented with 10% FBS. The media formulation for the
HOG cell line was also supplemented with a mixture of penicillin
(50 U/mL) and streptomycin (50 mg/mL).
Flow Cytometry
Cell lines were detached from tissue culture plates by incubation
with 10 mM EDTA in PBS for 5 min at 37uC, then washed in
PBS. For cell-surface staining, 2610
5 cells were resuspended in
50 ml of PBS containing 1% BSA, then incubated with immuno-
globulin for 1 hour on ice. Serum-derived IgG was added to each
sample to achieve a final concentration of 50 mg/ml, while
recombinant IgG were used at 5 mg/ml. The cells were then
washed in ice-cold PBS three times, then incubated with goat anti-
human IgG conjugated to AlexaFluor 647 (1:1000; Molecular
Probes) for one hour on ice, washed as indicated above then
resuspended in PBS. Propidium iodide (PI) (eBioscience) was then
added to exclude nonviable cells from the analysis. Cells were
analyzed by flow cytometry within 1 hour of addition of PI.
Samples for each cytometry were prepared and analyzed on the
same day to exclude the introduction of variability. For in-
tracellular staining, cells were first incubated with LIVE/DEAD
fixable violet dead cell stain (Invitrogen) for 30 min on ice, then
fixed with fixation/permeabilization buffer (eBioscience) for
20 min on ice. The amount of IgG and goat anti-human IgG
used were the same as described for the cell surface staining.
Washing and fixation were performed using reagents and a pro-
tocol provided by the manufacturer. Cells were analyzed by flow
cytometry within 48 hours. Cell populations were analyzed using
an LSRII flow cytometer (BD Biosciences). Forward and side
scatter gating was used to exclude cell fragments and debris. Dead
cells were eliminated from the analysis through the use of the
viability reagent. Binding of IBM-derived IgG to the cell lines
(median fluorescence intensity) was compared to cells stained with
healthy donor and control-derived IgG. Populations were com-
pared using the two-tailed Mann-Whitney U test.
Immunohistochemistry
Frozen tissue sections (20 mm) of mouse quadriceps were
provided on microscope slides. Prior to immunohistochemistry,
the tissue was fixed in acetone at 220uC for three minutes and air
dried at room temperature. Sections were rinsed in PBS and
blocked with PBS containing 5% goat serum for one hour. After
incubation with 50 mg/ml of IgG for four hours at room
temperature, slides were rinsed three times in PBS followed by
incubation with goat anti-human IgG conjugated to AlexaFluor
488 (1:1000; Molecular Probes) for 1 hour. Slides were rinsed,
stained with the nuclear dye DAPI (1 mg/ml; Sigma) for 10
minutes, rinsed and mounted with FluorSave
TM Reagent
(Calbiochem). Fluorescent images were captured with a Zeiss
AxioScope.
Expression of Recombinant IgG
Recombinant IgG was prepared from single plasma cells
isolated from IBM muscle tissue specimens and controls using
an approach similar to that, which has been described previously,
although minor modifications were introduced. Individual cells
Humoral Autoimmunity in Inclusion Body Myositis
PLOS ONE | www.plosone.org 2 October 2012 | Volume 7 | Issue 10 | e46709were isolated from tissue sections using laser capture micro-
dissection [12,21]. Single cell PCR was used to amplify the
immunoglobulin variable heavy and light chains [21,22]. These
products were subsequently directionally sub-cloned behind the
CMV promoter into a pcDNA3.3-based vector constructed in-
house to harbor the human immunoglobulin constant domains
(heavy and light chains). The heavy chain vector was modified to
contain a C-terminal affinity tag (HA-hemagglutinin). The final
constructs were engineered such that the rIgG produced did not
include any non-native residues that can arise from inclusion of
restriction enzyme sites and other engineering artifacts. Expression
was achieved by transfecting a heavy and light chain-containing
plasmid pair into CHO-S cells that have been adapted to grow in
suspension and in a media that does not contain protein or require
the addition of serum. Following transfection, cells were propa-
gated for 6 days, and then the supernatant (containing the secreted
rIgG) was collected and applied to a protein-G Sepharose column,
which yielded purified rIgG upon elution [23,24]. The rIgG-6,
6Hd1, 6Hd2 and 6HA1 were all obtained from the same muscle
specimen, rIgG-5, rIgG-2 and rIgG-86H was each derived from
unique muscle specimens. Serum samples matching these biopsy
specimens were not available. Six rIgGs were used for the flow
cytometry analyses (rIgG-2 was not included). Two (rIgG-5 and
rIgG-2) were used for the immunoblotting.
Immunoblotting and Mass Spectrometry
Human muscle tissue lysates (25 mg) were separated on 12%
SDS-PAGE gels. Proteins were transferred to nitrocellulose
membranes, then blocked in TBS-T (Tris buffered saline pH7.4,
0.05%Tween) containing 5% non-fat dry milk for 1 hour. The
membranes were then incubated with recombinant IgG (10 mg/
ml) overnight at 4uC. The membranes were washed 3 times with
TBS-T and incubated with a HRP-conjugated anti-HA antibody
(Roche) diluted 1:500 in blocking buffer for one hour, washed as
above then binding detected using enhanced chemiluminescence
(ECL) Western blotting reagents (GE Healthcare). Bands were
visualized on autoradiography film.
For mass spectrometry, human muscle tissue lysates were
separated by SDS-PAGE, and then the protein bands were
visualized with Coomassie staining. Bands of interest were excised
from the gel, reduced, alkylated and digested with trypsin. The
resulting peptides were extracted with organic solvents and
concentrated to a fixed volume. The peptides were then applied
to a capillary reverse phase (Phenomenex, Inc. Jupiter C18) high
performance liquid chromatography (HPLC) column. Individual
peptides were eluted with a linear gradient from 0–40%
acetonitrile in formic acid (0.1%) using a Waters NanoAcuity
HPLC and autosampler. The HPLC column was physically
coupled to the tandem mass spectrometer in a nanospray
configuration, such that the column eluate flowed directly into
an ion trap mass spectrometer (ThermoFisher LTQ). For protein
identification, ThermoScientific SEQUEST software was used to
identify peptides. We narrowed our list of candidate proteins by
selecting proteins of 50–60 kDa (near the size of the band in the
immunoblot).
ELISA
A 96-well plate was coated (250 ng/well) with commercially
acquired Desmin and Vimentin (GenWay Biotech, San Diego,
CA). The wells were blocked with PBS +2% BSA followed by
addition of recombinant IgG at 10 mg/ml. Serial three-fold
dilutions of the recombinant IgG were made to obtain a binding
curve. Bound immunoglobulin was detected with a monoclonal
peroxidase conjugated anti-HA antibody. The HRP-labeled
secondary antibody was visualized using the peroxidase substrate,
TMB (100 ml/well). The addition of 100 ml of 1 M hydrochloric
acid stopped color development. Absorbance was measured at
450 nm on a mQuant
TM Microplate Spectrophotometer.
Statistical Analysis
Median fluorescence intensity (MFI) of different groups was
compared using the Mann-Whitney test. All statistical analysis was
performed using Prism 4.02 software (Graph Pad).
Results
IBM Serum-derived IgG Binds Muscle-associated Self-
antigens
To assess whether IBM serum-derived antibodies recognize self-
antigens, we purified IgG from the serum of IBM patients and
control subjects and looked for binding to muscle tissue sections by
immunohistochemistry. To evaluate IgG binding to muscle
antigens by immunohistochemistry, murine-derived tissue was
favored over human as the latter provides high background due to
endogenous immunoglobulin, which would be detected with our
anti-human Ig secondary detection reagent. Moreover, purified
immunoglobulin was used in preference to serum as the latter
often produces a signal that includes nonspecific binding and does
not allow precise control over the concentration of IgG among
different specimens used in the assay. All nine IBM serum-derived
IgG specimens demonstrated binding to muscle tissue sections
with strong staining to the endomysial membrane (Figure 1A–I). In
six of these samples binding was also observed in the perimysium
(Figure 1C, D and F–I). In contrast, no binding was observed to
adjacent tissue sections that were stained with serum-derived IgG
from healthy donors (Figure 1J–L). Binding by IBM and control
IgG was not observed when brain tissue sections were used (not
shown). These data suggest that the peripheral circulation of IBM
patients includes autoantibodies directed towards self-antigens that
are present in muscle tissue.
IBM Serum-derived IgG Binds to the Muscle Cell Lines
CCL-136 and CRL-1598
To complement the IBM serum autoantibody binding observed
with the muscle tissue sections, we measured serum IgG binding to
cell surface determinants on human muscle-derived cell lines by
flow cytometry (Figure 2A). The human rhabdomyosarcoma cell
lines CCL-136 and CRL-1598 and a human oligodendrocyte-
derived cell line (HOG) were used to test binding to self-antigens
expressed by muscle (former two) and non-muscle cells (latter)
respectively (Figure 2A). A subset (5 of 9 (56%)) of the IBM serum-
derived IgG demonstrated binding to the cell surface of the muscle
cell lines CCL-136, while 2 of 9 (22%) bound to the CRL-1598 cell
line (Figure 2B). Healthy donor derived IgG (n=9) showed no
effective binding to either muscle cell line (Figure 2B). The binding
of the IBM serum-derived IgG to both the cell lines CCL-136
(p=0.0009) and CRL-1598 (p=0.05) was significantly different
from that of the healthy donor cohort (Figure 2B).
One IBM-derived IgG specimen (1 of 9 (11%)) bound to the
surface of human brain-derived HOG cell line (Figure 2B). This
specimen was among those that also bound to the CCL-136 and
CRL-1598 cell line, suggesting that these cell lines may share an
antigen recognized by this IBM serum specimen or that the serum
harbors multiple populations of autoantibodies of different
specificities. Healthy donor derived IgG (n=9) showed no effective
binding to the surface of the HOG cell line (Figure 2B). In addition
to cell surface staining, staining was also performed on the same
cell lines following permeabilization to allow for binding to
Humoral Autoimmunity in Inclusion Body Myositis
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binding (Figure. 2C) to permeablized CCL-136 (3 of 9 (33%)) and
CRL-1598 (2 of 9 (22%)) cell lines. The binding of the IBM serum-
derived IgG to the cell lines CCL-136 (p=0.005), CRL-1598
(p=0.009) and HOG (p=0.009) was significantly different to that
of the healthy donor cohort. These IBM specimens were among
the six that also recognized antigens expressed on the surface of
CCL-136 and CRL-1598 cells. Healthy donor derived IgG (n=9)
showed minimal binding to both permeabilized muscle cell lines
and the HOG cell line (Figure 2C).
Taken together, these data further suggest that the peripheral
circulation of patients with IBM, analogous to other autoimmune
conditions, includes autoantibodies that recognize both extra- and
intracellular self-antigens expressed by human cells, including, but
not limited to, those derived from muscle.
Figure 1. Immunostaining of muscle tissue with serum-derived IgG. Immunostaining of mouse muscle tissue demonstrates IBM-derived IgG
positively label muscle tissue sections (A–I). The identity of the IgG specimens is shown in the top right corner of each panel. Staining is present
within the endomysial space (green). Nuclei are stained in blue. In sections (A, C, D, F, G, H and I) IBM-derived IgG labeling can be seen in the
endomysial space. In six of these samples binding was also observed in the perimysium (C, D and F–I). Tissue, from adjacent sections, stained with IgG
derived from healthy donor (HD) serum (J–L) is free of any labeling.
doi:10.1371/journal.pone.0046709.g001
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Antibodies That Recognize Self-antigens
Having determined that IBM serum harbors self-reactive
immunoglobulin, we next focused our study at the site of IBM
tissue injury. Earlier studies, from our group and others,
established that antigen-experienced plasma cells reside in IBM
muscle tissue [7,11,12]. Thus, we reasoned that autoantigens
present in the damaged tissue might be the target of the antibodies
produced at this site. To explore this possibility we isolated single
plasma cells, directly from IBM-derived muscle tissue sections
using laser capture microdissection and from these cells, prepared
a series of recombinant immunoglobulins. Thus, each rIgG
represents the IgG produced by a single plasma cell residing in
the muscle tissue. These rIgG were used to assess whether IBM
tissue-associated plasma cells produce antibodies that recognize
self-antigens. Flow cytometry of the muscle-derived cell lines CCL-
136 and CRL-1598 was used to initially evaluate rIgG binding. A
humanized version of the monoclonal antibody 8-18C5 [23],
a widely used anti-myelin oligodendrocyte glycoprotein (MOG)
monoclonal antibody was used as a negative control as MOG is
not expressed by these cells (Figure 3). Of the six IBM-derived
recombinant IgGs examined, two rIgGs (rIgG-5 and rIgG-6,
obtained from two different IBM patients) demonstrated modest
binding to cell surface antigen(s) on CCL-136 and CRL-1598
relative to the control rIgG (Figure 3). The human oligodendro-
cyte-derived cell line (HOG) was used as a non-muscle control.
Both rIgG-6 and rIgG-5 did not bind to cell surface antigen(s) on
the HOG cell line (Figure 3). Curiously, when staining was
performed on these same cell lines following permeabilization,
strong binding was observed with the two rIgGs (rIgG-5 and rIgG-
6) that showed modest binding to extracellular determinants
(Figure 3). This binding was not restricted to muscle-derived cell
lines as both antibodies also bound to the permeabilized HOG cell
line suggesting that these antibodies may bind to an antigen shared
by all three cell lines. Binding of control rIgG 8-18C5 to
permeabilized cell lines was considerably lower than that observed
with IBM-derived rIgG-5 and rIgG-6. These data suggest that the
antigen-experienced plasma cells, associated with injured IBM
muscle tissue produce antibody that can recognize self-antigens.
Plasma Cells at the Site of IBM Tissue Injury Recognize
a Muscle-associated Antigen
Our observation that several of the rIgG derived from IBM
muscle specific plasma cells recognized self-antigens, prompted us
to search for their antigenic targets. We chose to focus on rIgG-5
because it provided the strongest binding to permeabilized cells,
suggesting that the target of rIgG-5 may be an intracellular
antigen. We used a human muscle tissue lysate as an antigen
source, as opposed to a muscle-derived cell line, as the latter would
include a more extensive representation of cellular components.
Immunoblots of tissue lysate with IBM-derived rIgG-5 revealed
a doublet near 55 kDa (Figure 4A, lane 1) that was not present in
the blots probed with a second rIgG derived from a plasma cell
(rIgG-2, lane 2) harbored by a different muscle specimen
(Figure 4A) or with two control rIgG (lanes 3 and 4). This
reactivity appeared to be restricted to muscle tissue as immuno-
blots performed with rIgG-5 on brain and spleen tissue lysates
failed to identify any bands (not shown).
To identify the target of rIgG-5 we took advantage of the harsh
extraction conditions required to solubilize the unknown target
antigen. As shown in Figure 4B, immunoblot analysis using rIgG-5
on a muscle tissue homogenate prepared using harsh extraction
conditions (lane 1) identified our band of interest that was not
present in a muscle lysate prepared using milder conditions (lane
2). To identify this protein target, both lysates were separated by
SDS-PAGE (Figure 4C) and bands corresponding to the size of
our protein of interest were extracted and analyzed by mass
spectrometry. By subtracting proteins identified using the mild
extraction conditions (in which the target was not present) from
those identified using the harsher conditions, we narrowed our list
of candidates to eight proteins. These included Desmin, Myotilin,
Tubulin, and Vimentin. We chose to focus on Desmin because
a total of 29 different peptides were identified, each of which
matched those found in human Desmin. By contrast Vimentin had
six, Myotillin five and Tubulin only two.
To assess whether rIgG-5 binds Desmin, we probed immuno-
blots of human muscle homogenate with both the IBM-derived
rIgG-5 recombinant immunoglobulin and a commercial anti-
human Desmin monoclonal antibody. Both antibodies produced
a single band of identical size (Figure 5A) that corresponded to the
molecular weight of human Desmin. Next, we probed immuno-
blots of purified human Desmin with rIgG-5 and a control rIgG
derived from a normal immature B cell (rIgG-D3a). The rIgG-5
recognized Desmin (lane 1) in the immunoblot while the control
rIgG (lane 2) did not (Figure 5B). We further established Desmin
as the target of rIgG-5 using ELISA with purified Desmin and
Vimentin. We chose Vimentin as a control due to its close
homology (69% at the amino acid level) with Desmin. Commer-
cially available monoclonal antibodies to Desmin (Figure 5C left
panel) and Vimentin (Figure 5C right panel) bound to their
respective antigens over IgG concentrations ranging from 0.02–
10 mg/mL. Control-derived rIgG-D3a did not bind Desmin or
Vimentin. IBM-derived rIgG-5 bound Desmin over a range of
antibody concentrations from 0.2–10 mg/mL, but did not bind to
Vimentin (Figure 5C). These data demonstrate that the IBM-
derived clone rIgG-5 recognizes human Desmin and indicates that
plasma cells at the site of IBM tissue injury can produce
autoantibodies.
Discussion
The current study was initiated to investigate the humoral
immune response in IBM and determine whether a component of
Figure 2. Cell-based assays to evaluate serum autoreactivity. A flow cytometry-based assay was used to evaluate IBM serum-derived IgG
binding to human muscle-derived cell lines CCL-136, CRL-1598 and the human CNS-derived oligodendrocyte cell line, HOG. (A) Positive staining in
the representative histograms is indicated by an increase in median fluorescence intensity (MFI) of an IBM-derived IgG (open curves) in comparison to
a representative healthy control-derived IgG (closed curves). Specimen IBM001 binds to permeabilized muscle (CCL-136, CRL-1598) and non-muscle
(HOG) cells but does not bind to cell surface components (extracellular staining). IBM003 binds to cell surface components of CRL-1598 while IBM005
binds to both CCL-136 and CRL-1598 cell lines. Both, IBM003 and IBM005 bind to permeabilized muscle cells (CCL-136 and CRL-1598). IBM003 binds
to both intra- and extra-cellular components of the HOG line while IBM005 does not bind to either intracellular or extracellular components on the
HOG cell line. The MFI values for all of the IBM serum-derived IgG specimens and controls are shown graphically. Assays performed with each of the
three cell lines to measure binding to extracellular (B) and permeabilized cell lines (C) were collected for two different populations (healthy subjects
and IBM patients). Each data point represents a single subject. The threshold line, above which specimens are considered positive, represents the
mean +2 standard deviations of the normal healthy control cohort. A subset of IgG derived from IBM bind to self-antigens expressed within and on
the surface of the cell lines tested.
doi:10.1371/journal.pone.0046709.g002
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support for the presence of a genuine humoral autoimmune
response both in the periphery and at the site of tissue damage in
IBM patients. The historical view of this disease has been that the
pathology is mediated by skeletal muscle degeneration and, in
part, by CD8+ T cells that are known to populate the damaged
tissue [1,9,25–28]. The data presented here contributes to an
emerging body of evidence [7,12,15] that suggests humoral
autoimmunity also occurs in patients with IBM. We have shown
that immunoglobulins that recognize self-antigen(s) can be
detected in the peripheral circulation of patients with IBM. Two
different, complementary techniques (immunohistochemistry and
flow cytometry) were used to demonstrate that such autoantibo-
dies exist. We extended our analysis to investigate the specificity of
the immunoglobulin expressed by plasma cells that populate the
damaged muscle tissue of patients with IBM. That we identified
a self-antigen as the target of the immunoglobulin produced by
IBM muscle tissue-associated plasma cells lends further evidence
to the concept that IBM includes humoral autoimmunity. It
further indicates that this autoimmune response is active, at least
in part, within the environment associated with tissue injury. It
should be noted that the co-existence of peripheral and localized
immune responses have been demonstrated in a number of
autoimmune diseases that include a humoral component.
Autoantibodies have been detected in the periphery and at the
site of tissue injury in rheumatoid arthritis where autoantibodies
are observed in both the circulation and the synovia of the joints
[29] and in neuromyelitis optica (NMO) where autoantibodies are
observed both in the periphery and in the central nervous system
[30].
While this study demonstrates that part of the humoral immune
response in IBM patients is directed towards self-antigens, we must
however stress that it remains unknown whether this response
actively contributes to disease pathogenesis or simply represents an
epiphenomenon. Furthermore, it remains likely that IBM is
a disease with multiple antibody specificities as seen with the other
inflammatory myopathies dermatomyositis and polymyositis,
where a wide spectrum of antigens [31], including nuclear and
cytoplasmic components have been identified. The heterogeneous
nature of the IBM humoral immune response is supported by
previous studies reporting autoantibodies in IBM patients to
a number of targets [31] with one study reporting that 44% of
IBM patients display autoantibodies to one or more of nine non-
disease specific targets [32]. However deciphering which auto-
antibodies are IBM specific will require some care as approxi-
mately 13% of IBM patients are reported to share coexisting
conditions that may account for some of the observed reactivity
[32,33]. One recent study reported the identification of a humoral
immune response in half of all IBM patients to a 43 kDa muscle
protein [15] that appears to be disease specific.
In this study, we identified the intermediate filament, Desmin
as the target of the immunoglobulin produced by a single
Figure 3. Cell-based assays to evaluate muscle-derived recombinant IgG autoreactivity. Recombinant IgG was prepared from single
muscle tissue-associated plasma cells. A flow cytometry-based assay was then used to evaluate the binding of this rIgG to human muscle cell lines
CCL-136, CRL-1598 and the human CNS-derived oligodendrocyte cell line, HOG. Representative positive staining shown in the histograms is indicated
by an increase in median fluorescence intensity (MFI) of the IBM-derived rIgG (open curves) in comparison to staining with the secondary antibody
alone (anti-human IgG-Alexa Fluor 647). A humanized monoclonal antibody, 8-18C5, specific for myelin oligodendrocyte glycoprotein served as
negative control. The evaluation of extracellular binding revealed a modest increase in MFI for rIgG-5 (open curves) and rIgG-6 (open curves) with
respect to the secondary antibody for both muscle-derived cell lines, but not the CNS-derived cell line. Both rIgG-5 and rIgG-6 demonstrate
detectable binding to all three permeabilized cell lines.
doi:10.1371/journal.pone.0046709.g003
Humoral Autoimmunity in Inclusion Body Myositis
PLOS ONE | www.plosone.org 7 October 2012 | Volume 7 | Issue 10 | e46709Figure 4. Autoantigen isolation and identification strategy. Recombinant IgG derived from an IBM muscle plasma cell was used to isolate an
unidentified target antigen. Muscle tissue homogenates (25 mg) were resolved by SDS-PAGE, then stained with coomassie brilliant blue or transferred
to nitrocellulose. Molecular weight markers (kDa) are indicated on the left of all panels. An immunoblot (A) of muscle tissue homogenate probed with
rIgG derived from a single IBM-tissue associated plasma cell (rIgG-5) demonstrated binding to a candidate antigen (lane 1). Binding was not present
with the rIgG-2 (lane 2), derived from a different muscle specimen or with control antibodies, D3a (lane 3) and 18/2 (lane 4) that were derived from
a healthy donor and from a patient with lupus respectively. A second immunoblot (bottom) probed with anti-HSP70 served as a loading control. (B)
Two separate human skeletal muscle homogenates prepared using either stringent (lane 1) or mild protein extraction conditions (lane 2) were
resolved by SDS-PAGE gel, and then transferred to nitrocellulose. Immunoblotting with rIgG-5 (lane 1), demonstrated the target antigen was present
when the homogenate was prepared with the stringent extraction, but not with the mild conditions (lane 2). An immunoblot (bottom) with HSP70
served as a loading control. (C) To isolate the candidate antigen, the two homogenates were separated by SDS-PAGE, then bands with the
approximate molecular weight of the candidate antigen were excised from the gel. Lane 1, muscle homogenized with the stringent extraction
procedure; Lane 2, molecular weight markers; Lane 3, muscle homogenized with the mild extraction procedure. These excised proteins were digested
with trypsin and the resulting peptides separated by reverse-phase chromatography, then applied to a mass spectrometer. Proteins present in lane 3
were subtracted from those identified in lane 1 to reduce the complexity of the mass spectrometry data set.
doi:10.1371/journal.pone.0046709.g004
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patient. Interestingly, Desmin has been identified as an
autoantigen in other autoimmune diseases [17–19] and is
therefore not uniquely associated with IBM. However, relevant
to the objectives of our study, the identification of this
autoantibody-autoantigen pair provides evidence that self-re-
active antibodies are produced by tissue infiltrating plasma cells.
As Desmin is an intracellular protein it is unlikely that this
reactivity represents an initiating event that leads directly to the
development of IBM. Such intracellular autoantibodies are often
useful as diagnostic or prognostic markers for disease. Yet, it is
possible that this reactivity contributes to disease following initial
muscle damage and the release of intracellular antigens.
Interestingly, Desmin is upregulated in all three inflammatory
myopathies [34]. However, it is unclear whether this upregula-
tion is a degeneration-induced effect. That we found this
reactivity in a single subject prohibits establishing a connection
between Desmin and IBM. The presence of such autoantibodies
may indeed not be a frequent event in this disease. Studies
regarding the prevalence of autoantibodies to Desmin in
patients with IBM, which will shed light on this, are underway.
Conclusions
Taken together, our description of antibodies directed against
self-antigens suggests that there is a humoral autoimmune
component in IBM – at least in a subset of patients. Our results
should trigger investigations that would set out to identify and
validate additional autoantigens and determine whether such
autoantibodies participate in disease pathology and if they can
serve as useful diagnostic or prognostic biomarkers that are
lacking for IBM. Additionally, investigations regarding the
mechanism and functional effects of the humoral branch of
the immune system in IBM pathophysiology need to be
initiated.
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Figure 5. Immunoassays evaluating recombinant IgG binding to Desmin. Independent immunoassays were used to demonstrate that
recombinant immunoglobulin derived from an IBM muscle-associated plasma cell (rIgG-5) binds to human Desmin. (A) Human muscle homogenates
were resolved by SDS-PAGE then transferred to membranes that were probed with IBM-derived recombinant rIgG-5 (lane 1) or a commercial anti-
Desmin monoclonal antibody (lane 2). (B) Purified human Desmin was resolved by SDS-PAGE then transferred to membranes that were probed with
IBM-derived rIgG-5 (lane 1) or rIgG-D3a (lane 2), which was derived from an immature antigen-inexperienced peripheral human B cell. (C) ELISA assays
demonstrating IBM-derived immunoglobulin (rIgG-5) binding to the human muscle protein Desmin. ELISA plates were coated with either Desmin (left
panel) or Vimentin (right panel) then probed with IBM rIgG-5 and a rIgG (D3a) derived from a single B cell from a normal healthy donor. Monoclonal
antibodies (mAb) specific for each antigen were used as positive controls.
doi:10.1371/journal.pone.0046709.g005
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